This inhibitor has shown efficacy in preclinical studies for PI3K‐driven tumours (Yu et al, 2015, 2017) and Proteus syndrome (Lindhurst et al, 2015), which is caused by a somatic AKT gain‐of‐function mutation. The gene discussed is PIK3CA; the disease is neoplasm.